Anne Madroszyk

2.3k total citations
60 papers, 706 citations indexed

About

Anne Madroszyk is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Anne Madroszyk has authored 60 papers receiving a total of 706 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 10 papers in Epidemiology. Recurrent topics in Anne Madroszyk's work include Lung Cancer Treatments and Mutations (22 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Lung Cancer Research Studies (13 papers). Anne Madroszyk is often cited by papers focused on Lung Cancer Treatments and Mutations (22 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Lung Cancer Research Studies (13 papers). Anne Madroszyk collaborates with scholars based in France, United States and Italy. Anne Madroszyk's co-authors include Karine Bardonnet, Frédéric Mauny, Gabriel Reboux, Jean‐Charles Dalphin, Renaud Piarroux, Laurence Millon, Anthony Gonçalvès, C. Chouaïd, G. Robinet and H. Léna and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and Clinical Cancer Research.

In The Last Decade

Anne Madroszyk

52 papers receiving 686 citations

Peers

Anne Madroszyk

PRM

ONCOL

SURGE

PFM

Chen Zhou Canada

Juliana Andrici Australia

S. Caruso Italy

Masatoshi Kida United States

Xiaoyan Liao United States

Enda Yu China

Akiko Kawakita Japan

James Conner Canada

Valérie Mialou France

Takafumi Fujino Japan

Chen Zhou Canada

Anne Madroszyk

157 ×0.4

PRM

307 ×1.0

ONCOL

95 ×0.7

105 ×0.9

SURGE

31 ×0.4

PFM

Citations per year, relative to Anne Madroszyk Anne Madroszyk (= 1×) peers Chen Zhou

Countries citing papers authored by Anne Madroszyk

Since Specialization

Citations

This map shows the geographic impact of Anne Madroszyk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Madroszyk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Madroszyk more than expected).

Fields of papers citing papers by Anne Madroszyk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Madroszyk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Madroszyk. The network helps show where Anne Madroszyk may publish in the future.

Co-authorship network of co-authors of Anne Madroszyk

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Madroszyk. A scholar is included among the top collaborators of Anne Madroszyk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Madroszyk. Anne Madroszyk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gobbini, Élisa, Mamadou Diallo, Dominique Pasquier, et al.. (2025). Clinical characteristics and management of long survivors in extensive stage small cell lung cancer. Lung Cancer. 202. 108499–108499.

Guisier, Florian, Pernelle Lavaud, Laurent Greillier, et al.. (2024). Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study. ESMO Open. 9(12). 103968–103968. 2 indexed citations

Dall’Olio, Filippo Gustavo, Bastien Job, Stefan Michiels, et al.. (2024). Genomic instability in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/ IFCT1301 trial.. Journal of Clinical Oncology. 42(16_suppl). 2632–2632. 1 indexed citations

Dall’Olio, Filippo Gustavo, Damien Vasseur, Maryam Karimi, et al.. (2023). Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.. Journal of Clinical Oncology. 41(16_suppl). 2516–2516.

Amodru, Vincent, Jean‐Marie Boher, Christophe Zemmour, et al.. (2023). Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records. Journal for ImmunoTherapy of Cancer. 11(8). e006786–e006786. 4 indexed citations

Rochigneux, Philippe, Aaron Lisberg, Alejandro J. Garcia, et al.. (2022). Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer. Clinical Cancer Research. 28(23). 5136–5148. 20 indexed citations

Besse, Benjamin, M.R. García Campelo, Élisabeth Quoix, et al.. (2021). LBA47 Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial. Annals of Oncology. 32. S1325–S1325. 11 indexed citations

Remón, Jordi, Benjamin Besse, Alexandra Léary, et al.. (2020). Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial. JTO Clinical and Research Reports. 1(3). 100068–100068. 19 indexed citations

Rochigneux, Philippe, Alejandro J. Garcia, Brice Chanez, et al.. (2020). Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review. Frontiers in Immunology. 11. 1036–1036. 11 indexed citations

10.

Giaccone, Giuseppe, Enriqueta Felip, Manuel Cobo, et al.. (2020). 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial. Annals of Oncology. 31. S814–S815. 9 indexed citations

11.

Rochigneux, Philippe, Aaron Lisberg, Anne-Sophie Chrétien, et al.. (2019). P1.04-33 Deep Phenotyping of Immune Populations Reveals Baseline Predictors of Pembrolizumab Efficacy in NSCLC on KEYNOTE-001. Journal of Thoracic Oncology. 14(10). S452–S453. 2 indexed citations

12.

Sabatier, Renaud, A.‐P. Jonville‐Béra, Anne Madroszyk, et al.. (2018). Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer. Journal of Geriatric Oncology. 9(5). 494–500. 17 indexed citations

13.

Levra, Matteo Giaj, Silvia Novello, Fausto Barbieri, et al.. (2017). P1.06-005 An International Cohort of Patients with Small Cell Lung Cancer after a Non-Small Cell Lung Carcinoma Oncogene or Non-Oncogene Addicted. Journal of Thoracic Oncology. 12(1). S667–S667.

14.

Chanez, Brice, François Bertucci, Marine Gilabert, et al.. (2017). A scoring system to guide the decision for a new systemic treatment after at least two lines of palliative chemotherapy for metastatic cancers: a prospective study. Supportive Care in Cancer. 25(9). 2715–2722. 3 indexed citations

15.

Caillaud, D., et al.. (2012). Bronchoalveolar Lavage in Hypersensitivity Pneumonitis: A Series of 139 Patients. Inflammation & Allergy - Drug Targets. 11(1). 15–19. 34 indexed citations

16.

Tabouret, Émeline, Maryline Barrié, Cécile Vicier, et al.. (2012). Association of carcinoid tumor and low grade glioma. World Journal of Surgical Oncology. 10(1). 236–236. 1 indexed citations

17.

Borget, Isabelle, Jacques Cadranel, Jean‐Pierre Pignon, et al.. (2011). Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. European Respiratory Journal. 39(1). 172–179. 27 indexed citations

18.

Gilabert, Marine, François Bertucci, Benjamin Esterni, et al.. (2011). Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.. PubMed. 31(3). 1079–86. 15 indexed citations

19.

Limat, Samuel, et al.. (2004). From Randomised Clinical Trials to Clinical Practice. PharmacoEconomics. 22(10). 633–641. 12 indexed citations

20.

Reboux, Gabriel, Renaud Piarroux, Frédéric Mauny, et al.. (2001). Role of Molds in Farmer's Lung Disease in Eastern France. American Journal of Respiratory and Critical Care Medicine. 163(7). 1534–1539. 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact